Quick Answer
Acrivon Therapeutics, Inc. reported Stockholders Equity of $112.52 million for the year ending 2025.
- Acrivon Therapeutics, Inc. showed a decrease of -36.4% in Stockholders Equity from 2024 to 2025.
- This data is from Acrivon Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$14.84 million | Q2 2021: -$17.36 million | Q3 2021: -$19.77 million | Q1 2022: -$30.99 million | Q2 2022: -$36.58 million | Q3 2022: -$45.62 million | Q1 2023: $160.47 million | Q2 2023: $149.18 million | Q3 2023: $138.15 million | Q1 2024: $107.98 million | Q2 2024: $216.06 million | Q3 2024: $196.89 million | Q1 2025: $160.39 million | Q2 2025: $143.04 million | Q3 2025: $128.60 million.
- Over the full 6 years of available data (2020 to 2025), Acrivon Therapeutics, Inc.'s Stockholders Equity has grown by 1,437.4%.
- Historical annual values: Fiscal year 2025: $112.52 million | Fiscal year 2024: $176.79 million | Fiscal year 2023: $121.20 million | Fiscal year 2022: $170.48 million | Fiscal year 2021: -$23.81 million | Fiscal year 2020: -$8.41 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: